Trial Finds Wegovy Improves Liver Fibrosis

Published on November 1, 2024

Novo Nordisk said on Friday its weight-loss drug met the main goal of a late-stage trial by showing improvement in liver fibrosis with no worsening of steatohepatitis. The trial, which studied 2.4 milligram dose of semaglutide, showed a statistically significant improvement…

Read Full Article (External Site)